Cargando…

HDAC Inhibitors in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled proliferation, differentiation arrest, and accumulation of immature myeloid progenitors. Although clinical advances in AML have been made, especially in young patients, long-term disease-free survival remains po...

Descripción completa

Detalles Bibliográficos
Autores principales:	San José-Enériz, Edurne, Gimenez-Camino, Naroa, Agirre, Xabier, Prosper, Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896008/ https://www.ncbi.nlm.nih.gov/pubmed/31739588 http://dx.doi.org/10.3390/cancers11111794

Ejemplares similares

Explainable artificial intelligence for precision medicine in acute myeloid leukemia
por: Gimeno, Marian, et al.
Publicado: (2022)

COBRA methods and metabolic drug targets in cancer
por: Apaolaza, Iñigo, et al.
Publicado: (2017)

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
por: San José-Enériz, Edurne, et al.
Publicado: (2009)

A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism
por: Apaolaza, Iñigo, et al.
Publicado: (2022)

BOSO: A novel feature selection algorithm for linear regression with high-dimensional data
por: Valcárcel, Luis V., et al.
Publicado: (2022)

An in-silico approach to predict and exploit synthetic lethality in cancer metabolism
por: Apaolaza, Iñigo, et al.
Publicado: (2017)

Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2018)

Identifying Lethal Dependencies with HUGE Predictive Power
por: Gimeno, Marian, et al.
Publicado: (2022)

Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia
por: Vilas–Zornoza, Amaia, et al.
Publicado: (2011)

DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters?
por: Ordoñez, Raquel, et al.
Publicado: (2019)

Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome
por: Rodriguez-Madoz, Juan Roberto, et al.
Publicado: (2017)

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer
por: Pey, Jon, et al.
Publicado: (2017)

Updates on the Management of Acute Myeloid Leukemia
por: Huerga-Domínguez, Sofía, et al.
Publicado: (2022)

Correction: Ordoñez, et al.; DNA Methylation of Enhancer Elements in Myeloid Neoplasms: Think Outside the Promoters? Cancers 2019, 11, 1424
por: Ordoñez, Raquel, et al.
Publicado: (2020)

The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
por: Masetti, Riccardo, et al.
Publicado: (2011)

Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
por: Fernandez-Mercado, Marta, et al.
Publicado: (2012)

DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia
por: Alvarez, Sara, et al.
Publicado: (2010)

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?
por: Losson, Hélène, et al.
Publicado: (2020)

Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma
por: Amundarain, Ane, et al.
Publicado: (2022)

Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated
por: Martínez-Calle, Nicolás, et al.
Publicado: (2019)

Checkpoint Inhibitors in Acute Myeloid Leukemia
por: Damiani, Daniela, et al.
Publicado: (2023)

HDAC2‐dependent miRNA signature in acute myeloid leukemia
por: Conte, Mariarosaria, et al.
Publicado: (2019)

HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
por: Spreafico, Marco, et al.
Publicado: (2020)

Long Non-Coding RNAs in Haematological Malignancies
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2013)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

FLT3 inhibitors in acute myeloid leukemia
por: Wu, Mei, et al.
Publicado: (2018)

Bcr/Abl Interferes with the Fanconi Anemia/BRCA Pathway: Implications in the Chromosomal Instability of Chronic Myeloid Leukemia Cells
por: Valeri, Antonio, et al.
Publicado: (2010)

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma
por: De Beck, Lien, et al.
Publicado: (2022)

Natural Inhibitors of P-glycoprotein in Acute Myeloid Leukemia
por: Labbozzetta, Manuela, et al.
Publicado: (2023)

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2021)

The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients
por: Villar, Sara, et al.
Publicado: (2022)

The Role of lncRNAs in the Pathobiology and Clinical Behavior of Multiple Myeloma
por: Carrasco-León, Arantxa, et al.
Publicado: (2021)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

Clinical use of FLT3 inhibitors in acute myeloid leukemia
por: Sutamtewagul, Grerk, et al.
Publicado: (2018)

FLT3 inhibitors: clinical potential in acute myeloid leukemia
por: Hospital, Marie-Anne, et al.
Publicado: (2017)

Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
por: Takahashi, Shinichiro
Publicado: (2023)

Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels
por: Guillaumet-Adkins, Amy, et al.
Publicado: (2014)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3jju8424747l4qt7hjosghnkvg